Navigation Links
Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
Date:6/4/2013

MENLO PARK, Calif., June 4, 2013 /PRNewswire/ -- Protagonist Therapeutics, Inc. today announced the completion of a $14 million Series B venture financing. The financing, led by new investor Johnson & Johnson Development Corporation (JJDC), also included the participation of Series A investors Lilly Ventures and Starfish Ventures (Melbourne, Australia).  The new funding will support the discovery and development of Protagonist's pipeline of oral di-sulfide rich peptide (DRP) therapeutics that combine the best properties of small molecule drugs and large molecule biologics in a single chemical entity.

(Logo: http://photos.prnewswire.com/prnh/20130501/MM06086LOGO)

As part of the transaction, Asish K. Xavier , Ph.D., Vice President, Venture Investments at JJDC, will join the Protagonist Board as a Director.

"This participation by JJDC as a new investor, along with the continued support from major existing investors Lilly Ventures and Starfish Ventures creates a strong syndicate and adds a new dimension in the growth of Protagonist.  The new financing will serve to support R&D efforts for the internal programs focused on well-differentiated applications of oral peptides to novel targets for diseases where neither small molecules nor biologics can currently offer a good solution," said Dinesh V. Patel , Ph.D., President and Chief Executive Officer of Protagonist Therapeutics.

"Previously, we have validated our technology platform through selective collaborations with leading companies in the field of peptide therapeutics.  We are very committed to these partnerships and will continue to enhance these synergistic relationships over the years to come," added Dr. Patel.  "This Series B financing allows us to leverage our internal discovery engine, giving Protagonist the opportunity of having multiple internal and collaborative clinical assets by 2015-16."

About Protagonist Therapeutics
Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable. DRPs are a proven chemical class of drugs with numerous examples of orally stable and injectable NCEs on the market and in various stages of clinical development. The company has a validated technology platform well suited to explore the full potential of the DRP scaffold class. It comprises of a purposefully built computational design environment, directed evolution approaches to prepare millions of molecules via phage libraries, and classical small molecule medicinal chemistry-type analoging and SAR development.

Protagonist is a spin-out of University of Queensland's Institute of Molecular Biosciences (IMB) and has discovery operations in Menlo Park, California USA and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.


'/>"/>
SOURCE Protagonist Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Protagonist Therapeutics Names David Liu Chief Scientific Officer
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... procedure that achieves results in a fraction of the time as traditional braces ... with Significance Dental Specialists, now offers this revolutionary treatment with or without a ...
(Date:4/25/2017)... ... 2017 , ... Back Pain Centers of America (BPC), which connects ... in their area, announces the launch of a new and proprietary customer relationship management ... for reputable physicians to help them with back or neck pain and helps to ...
(Date:4/25/2017)... Santa Clara, CA (PRWEB) , ... April 25, ... ... technology, announces the addition of predictive analytics to its patient care management module. ... therapy compliance even before a patient has been initiated on continuous positive airway ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at ... and joint health in horses at the immunologic level. , The scientifically-developed Flexadin ...
Breaking Medicine News(10 mins):